| Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. | |
| | |
MedLine Citation:
|
PMID: 19383643 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes, with some members being implicated in the immunopathogenesis of multiple sclerosis (MS). Interferon (IFN)-beta is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9. However, only sparse information is available on the effects of IFN-beta on the other 20 members of the MMP family. METHODS: This is a longitudinal analysis on the RNA expression pattern of all known MMPs and their endogenous inhibitors before and after 1 and 6 months of IFN-beta therapy. RNA expression levels were assessed in peripheral venous blood cells from 14 MS patients and 8 matched controls by real time-PCR. RESULTS: RNA expression levels before treatment differed in part in MS patients compared to healthy controls (MMP-9, MMP-14, MMP-19, TIMP-1, TIMP-2). Some of the MMPs responded to therapy specifically (MMP-8, MMP-9, MMP-19), whereas others remained unchanged over time. CONCLUSIONS: These data suggest that MMPs may differ in their expression levels in MS patients and that this group of enzymes is differentially regulated during the treatment with IFN-beta in MS for at least 6 months. |
| | |
Authors:
|
F Bernal; B Elias; H P Hartung; B C Kieseier |
Related Documents
:
|
21092323 - Calmodulin kinase ii-dependent transactivation of pdgf receptors mediates astrocytic mm... 16753323 - Expression of fugu timp-3 and -4 genes in adult tissues and embryos. 10692433 - Cdk2-dependent and -independent pathways in e2f-mediated s phase induction. |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't Date: 2009-04-21 |
Journal Detail:
|
Title: Multiple sclerosis (Houndmills, Basingstoke, England) Volume: 15 ISSN: 1352-4585 ISO Abbreviation: Mult. Scler. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-01 Completed Date: 2009-08-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9509185 Medline TA: Mult Scler Country: England |
Other Details:
|
Languages: eng Pagination: 721-7 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich-Heine-University, Düsseldorf, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Female Gene Expression Regulation, Enzymologic / drug effects Humans Immunologic Factors / therapeutic use Interferon-beta / therapeutic use* Leukocytes / drug effects, physiology Longitudinal Studies Male Matrix Metalloproteinase 14 / genetics Matrix Metalloproteinase 8 / genetics Matrix Metalloproteinase 9 / genetics Matrix Metalloproteinases / genetics* Matrix Metalloproteinases, Secreted / genetics Middle Aged Multiple Sclerosis, Relapsing-Remitting / drug therapy*, metabolism* RNA, Messenger / metabolism Reverse Transcriptase Polymerase Chain Reaction Tissue Inhibitor of Metalloproteinase-1 / genetics* Tissue Inhibitor of Metalloproteinase-2 / genetics* |
| Chemical | |
Reg. No./Substance:
|
0/Immunologic Factors; 0/RNA, Messenger; 0/Tissue Inhibitor of Metalloproteinase-1; 127497-59-0/Tissue Inhibitor of Metalloproteinase-2; 77238-31-4/Interferon-beta; EC 3.4.24.-/Matrix Metalloproteinases; EC 3.4.24.-/Matrix Metalloproteinases, Secreted; EC 3.4.24.-/matrix metalloproteinase 19; EC 3.4.24.34/Matrix Metalloproteinase 8; EC 3.4.24.35/Matrix Metalloproteinase 9; EC 3.4.24.80/Matrix Metalloproteinase 14 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Uncommon acquired Gerbode defect (left ventricular to right atrial communication) following a tricus...
Next Document: Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation...